Confusion: Acetaminophen dosing changes based on NO evidence in adults

Drugs in R and D

Volumn 12, Issue 2, 2012, Pages 45-48

  Krenzelok, Edward P ^a,b   Royal, Mike A ^c,d  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Cadence Pharmaceuticals   (United States)

^d University of California   (United States)

Author keywords

Drug overdose; Liver injury; Paracetamol; Regulatory process

Indexed keywords

PARACETAMOL;

ACUTE LIVER FAILURE; DRUG APPROVAL; DRUG FORMULATION; DRUG SAFETY; EMERGENCY HEALTH SERVICE; FOOD AND DRUG ADMINISTRATION; HOSPITAL DISCHARGE; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; TOXIC HEPATITIS; UNITED STATES;

ACETAMINOPHEN; ADULT; ANALGESICS, NON-NARCOTIC; DRUG LABELING; DRUG-INDUCED LIVER INJURY; HUMANS; NONPRESCRIPTION DRUGS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84863711363     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/bf03262189     Document Type: Review

References (13)

1. Ganley C. Memorandum, January 15, 2002; an archeological review of the regulatory history of over-the-counter (OTC) single ingredient acetaminophen [online]. Available fromURL: Http://www.fda.gov/ohrms/dockets/ac/02/briefing/ 3882b1-02-A-1-History-%20Supporting%20Documents.pdf [Accessed 2012 Jan 25]
2. Drug Safety and Risk Management Advisory Committee. Acetaminophen: background and overview [online]. Available from URL: http://www.fda.gov/ downloads/Advisory Committees/CommitteesMeetingMaterials/Drugs/DrugSafety andRiskManagementAdvisoryCommittee/UCM175767.pdf [Accessed 2012 Feb 21]
3. Department of Health and Human Services, Food and Drug Administration. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; proposed amendment of the tentative final monograph; required warnings and other labeling. Fed Regist 2006; 71: 77314-52 [online]. Available from URL: http://www.gpo.gov/fdsys/pkg/FR-2006-12-26/pdf/E6-21855.pdf [Accessed 2012 Apr 3]
4. Davidson DGD, Eastham WN. Acute liver necrosis following overdose of paracetamol. Br Med J 1966; 2: 497-499
5. Larson AM, Polson J, Fontana RJ, et al. Acetaminopheninduced acute liver failure: Results of a United States multicenter, prospective study. Hepatol 2005; 42: 1364-1372
6. Lee WM. Acetaminophen-related acute liver failure in the United States. Hepatol Res 2008; 38 Suppl. 1: S3-8
7. Khandelwal N, James LP, Sanders C, et al. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatol 2011; 53: 567-576
8. Budnitz DS, Lovegrove MC, Crosby AE. Emergency department visits for overdoses of acetaminophen-containing products. Am J Prev Med 2011; 40: 585-592
9. Krenzelok EP. The FDA Acetaminophen Advisory Committee meeting - What is the future of acetaminophen in the United States? The perspective of a committee member. Clin Toxicol 2009; 47: 784-789
10. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use [comment in JAMA 1994; 272: 1866-7; author reply in JAMA 1995; 274: 301]. JAMA 1994; 272: 1845-1850
11. den Hertog HM, van der Worp HB, van Gement HMA, et al. The Paracetamol (Acetaminophen) in Stroke (PAIS) trial: A multicentre, randomized, placebo-controlled, phase III trial. Lancet Neurol 2009; 8: 434-440
12. Temple AR, Benson GD, Zinsenheim JR, et al. Multicenter, randomized, double-blind, active-controlled, parallelgroup trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis. Clin Ther 2006; 28: 222-235
13. Jones VM. Acetaminophen injection: A review of clinical information. J Pain Palliative Care Pharmacother 2011; 25: 340-349